SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending downwards amidst discussions about earnings, where increased costs outpaced revenue growth. Concerns over valuation, the impact of expiring tax credits, and Elon Musk's proposed compensation package are also driving bearish sentiment. Despite this, some bulls remain optimistic, focusing on the potential of AI, energy storage, and robotaxis.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid discussions of the U.S. government potentially taking an equity stake in quantum computing firms, sparking excitement about the industry's future. Community members are debating whether this signals long-term growth potential or a short-term pump, with some highlighting the potential impact of government funding on the sector. The conversations also include mentions of quantum-resistant crypto and comparisons to other quantum computing stocks.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ is trending following news it demonstrated quantum-safe Bitcoin, which the community sees as essential for the future of cryptocurrency. Bullish investors highlight the company's first-mover advantage in quantum security and potential for government and institutional adoption. Some are also drawing comparisons to other quantum computing stocks and noting BTQ's smaller market cap.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as the community discusses the potential impact of government funding and equity stakes in quantum computing firms. Some believe this could lead to significant growth, while others view it as a short-term pump or a sign of government overreach. The stock's recent volatility and potential for both bullish and bearish scenarios are also being debated.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ ($LAES) is trending amid discussions around potential government investment in quantum computing firms, spurred by a *Wall Street Journal* report. The community is debating whether SEALSQ could benefit and some anticipate a potential short squeeze. Also, upcoming milestones around the release of the Quantum Shield QS7001 chip.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as traders analyze its potential breakout and resistance levels, while some discuss its AI advancements and partnerships, such as with DoorDash and Salesforce. Community members are actively debating whether the stock can sustain its upward momentum amid broader market concerns and competition from companies like OpenAI. Recent analyst upgrades and the anticipation of upcoming earnings are also fueling interest in GOOGL.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending as investors discuss the potential impact of the Trump administration considering equity stakes in quantum computing firms, a move that could mirror an "Intel model" for federal funding. Community talking points include speculation on whether the government is becoming a major venture capitalist and if this will drive QUBT higher. Some traders are wary of a potential pump and dump.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

Beasley Broadcast Group ($BBGI) is trending due to its low float, leading to speculation of a potential short squeeze similar to other recent runners. Community members are discussing the stock's chart setup and anticipating a breakout, with some setting ambitious price targets. However, some are cautioning about the company's financials, citing concerns about debt and revenue.

Houston American Energy Corp. is an independent oil and gas company, which engages in the development, exploration, exploitation, acquisition, and production of natural gas and crude oil properties. The firm holds interest in the Texas Permian Basin, the onshore Texas and Louisiana Gulf Coast region and in the South American country of Colombia. It operates through the North America and South America geographical segments. The company was founded on April 2, 2001 and is headquartered in Houston, TX.

Houston American Energy Corp

Houston American Energy (HUSA) is trending as traders discuss its potential movement alongside other oil stocks, with some highlighting its low float and sensitivity to geopolitical events. Community members are debating its long-term value amid news of acquisitions and recent trading patterns. Discussions also include mentions of potential catalysts like new sanctions and evolving situations in the Middle East.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

SLMT is trending due to its low float and high short interest, leading to speculation about a potential short squeeze, with some traders eyeing a move towards triple digits; the community is actively discussing its squeeze potential and technical indicators. The stock's connection to Solana is also a key talking point, with some believing that a rebound in Solana could positively impact SLMT.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Polaris (PII) stock witnessed price target hikes on Tuesday after the specialty vehicle manufacturer announced a deal to separate its Indian bike operations from its portfolio and into a standalone business.BofA analyst Alexander Perry raised the firm's price target on Polaris to $70 from $60 while keeping a ‘Neutral’ rating on the shares after the company agreed to sell a majority stake in Indian Motorcycle to California-headquartered private equity firm Carolwood, as per TheFly.Roth Capital analyst Scott Stember, meanwhile, raised the firm's price target on the stock to $54 from $41 and kept a ‘Neutral’ rating on the shares. While BofA’s new price target implies a potential upside of about 14% from the stock’s closing price on Monday, Roth Capital’s new target suggests a potential downside of about 12%.Shares of Polaris traded 13% higher on Tuesday at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PII">PII stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:587/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_14_at_1_23_30_PM_png_136d55f245.webp" alt="PII's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Oct. 14, 2025 | Source: Stocktwits" width="587" height="62"><figcaption>PII's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Oct. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the company’s move as a good decision.<stembedurl>https://stocktwits.com/Lying___Dandy/message/632206305</stembedurl>Polaris did not disclose the size of the deal with Carolwood on Monday but <a href="https://stocktwits.com/news-articles/markets/equity/polaris-stock-jumps-on-deal-to-sell-indian-bikes-brand/ch6mQ4ER3l1">said</a> the divestiture would boost Polaris's annualized adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by about $50 million and annualized adjusted earnings by $1 a share. The closing of the transaction is expected in the first quarter of 2026.CEO Mike Speetzen said the sale would enable Polaris to focus on the parts of its business that have the most growth potential. However, the company said it would continue to maintain a small equity position in the Indian Motorcycle business after the closing of the transaction.Polaris also said on Monday that it expects third-quarter sales to be at the high end of its previously issued guidance range of $1.6 billion to $1.8 billion. The company now anticipates third-quarter adjusted earnings per share to be in the range of $0.31 to $0.41, higher than its original expectations.Speetzen said the higher expectations are driven by higher-than-expected shipments, strong cost management, and ongoing progress within operational efficiency initiatives.PII stock is up by 20% this year and down by about 15% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bikes from Indian Motorcycle, owned by Polaris, at the Minneapolis Convention Center in 2014. (Photo By Marlin Levison/Star Tribune via Getty Images)

Polaris Stock Gets Price Target Hikes After Selling Indian Bike Business To Private Equity Firm

BofA analyst Alexander Perry raised the firm's price target on Polaris to $70 from $60 after the company agreed to sell a majority stake in Indian Motorcycle to California-headquartered private equity firm Carolwood.

Equity

BofA analyst Alexander Perry raised the firm's price target on Polaris to $70 from $60 after the company agreed to sell a majority stake in Indian Motorcycle to California-headquartered private equity firm Carolwood.


Ford Motor Co. (F) CEO Jim Farley reportedly believes that the elimination of federal tax credit on the purchase of electric vehicles and other Trump policies will sharply curtail EV demand in the U.S.Farley predicted the share of zero-emission vehicles could decline by half, according to a Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-30/ford-s-ceo-sees-trump-policies-cutting-us-ev-market-in-half?srnd=homepage-americas">report</a>. ZEVs currently account for 10% of the domestic market.&nbsp;“I wouldn’t be surprised if EV sales in the U.S. go down to 5%,” Farley said at a conference in Detroit, as reported by Bloomberg. The CEO, however, said the company is looking to add hybrid production to its battery and EV plants, the report noted.<a href="https://stocktwits.com/symbol/F">Ford shares</a> traded 1% lower on Tuesday afternoon at the time of writing. On Stocktwits, retail sentiment around the stock stayed within the ‘bullish’ territory, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_2_06_42_PM_png_de870fd3da.webp" alt="F's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="625" height="63"><figcaption>F's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>In the second quarter, Ford’s EV segment, known as Model e, saw its operating loss widen to $1.3 billion, pressured by tariffs and ramp-up costs at its new battery plant in Marshall, Michigan.Ford’s current EV lineup in the U.S. is comprised of just three vehicles: the F-150 Lightning pickup truck, the Mustang Mach-E SUV, and the E-Transit van. This year, through the end of August, the company sold a cumulative 57,888 units of the three models, marking a drop of about 6% from the corresponding period last year, despite a 5.5% increase in internal combustion engine vehicles.Ford stated last month that it plans to introduce a new group of affordable electric vehicles starting in 2027 to expand its EV lineup. The first in line would be a midsize pickup truck assembled at Ford’s Louisville Assembly Plant with an expected starting price of $30,000, the company added.F stock is up by about 21% this year and by about 13% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moonlake-immunotherapeutics-stock-draws-wall-street-attention-post-mondays-plunge/chDDKdWR39j">MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ford Motor Company CEO Jim Farley speaks at a Ford Pro Accelerate event on September 30, 2025 in Detroit, Michigan. (Photo by Bill Pugliano/Getty Images)

Ford CEO Jim Farley Reportedly Expects US EV Demand To Decline Sharply – Here’s Why

According to a Bloomberg report, Farley predicted the share of zero-emission vehicles could fall by half. 

Bristol Myers Squibb (BMY) announced on Thursday that it will sell its moderate-to-severe plaque psoriasis drug, Sotyktu, at a discount of more than 80% to the current list price, starting in January 2026, to cash-paying patients.Patients can purchase the drug at a discount on the company’s BMS Patient Connect direct-to-patient platform. Eligible cash-paying U.S. patients with a Sotyktu prescription can buy the medicine through the platform, which offers shipping across all 50 states and Puerto Rico, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Builds-on-Eliquis-apixaban-Direct-to-Patient-Program-Announces-New-BMS-Patient-Connect-Platform-Offering-Sotyktu-deucravacitinib/default.aspx">stated</a>. The platform will also provide patient support resources, it added.“We are taking a leading role in removing barriers, providing transparency and lowering out-of-pocket costs so patients in the United States can get the treatments they need – delivered directly to their door, wherever they are in the country,” CEO Christopher Boerner said.The announcement comes on the heels of President Trump <a href="https://stocktwits.com/news-articles/markets/equity/trump-to-issue-60-day-warning-letters-to-drugmakers-over-pricing/choL0IMRdGB">sending</a> letters to 17 drugmakers demanding that they lower drug prices in the U.S. to levels paid by other wealthy nations. The deadline for meeting the demand is on Monday, and the White House has warned of action against those who do not comply.Shares of the company traded 0.3% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BMY">BMY stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.In July, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://google.com/url?q=https://stocktwits.com/news-articles/markets/equity/bristol-myers-pfizer-to-offer-blood-thinning-drug-at-discount/ch8K8XqR5pI&amp;sa=D&amp;source=docs&amp;ust=1758807238695403&amp;usg=AOvVaw1vujNK93MaBpbwKU9R5Fiv">announced</a> that it will sell its blood thinner drug Eliquis to cash-paying patients for more than 40% discount to the current list price. Eliquis is a prescription medicine used in adults to reduce the risk of stroke and blood clots in people who have atrial fibrillation (AFib), a type of irregular heartbeat, not caused by a heart valve problem. It is also used to treat blood clots in the veins of the legs or lungs, and reduce the risk of them occurring again after receiving treatment for blood clots.BMY stock is down approximately 22% this year and by about 12% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-rises-pre-market-over-fresh-hopes-of-deramiocel-approval-in-treating-genetic-disorder/chDlIyZR34h">Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Bristol-Myers Squibb Company logo is seen displayed on a tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026

Patients can purchase the drug at a discount on the company’s BMS Patient Connect direct-to-patient platform.

Harmony Biosciences Holdings (HRMY) on Wednesday said that its late-stage study of ZYN002 in Fragile X syndrome did not meet the primary endpoint of improvement in social avoidance.Fragile X syndrome (FXS) is a rare genetic disorder that negatively affects synaptic function, plasticity, and neuronal connections. It results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability. According to the company, the disease affects upwards of 80,000 patients in the U.S. and 121,000 patients in the European Union and the U.K. The disease is more common in males than females, but there are no FDA-approved treatments for the disorder.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-provides-update-its-phase-3-reconnect-study">said</a> on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.Shares of HRMY traded 15% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:575/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_1_01_23_PM_png_17fb739829.webp" alt="HRMY's Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="575" height="62"><figcaption>HRMY's Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>Chief Medical Officer Kumar Budur stated that, although the study's findings did not meet the primary endpoint, they provide valuable insights into Fragile X syndrome. “We will conduct a comprehensive analysis of the full dataset to better understand the results as part of our continued commitment to the Fragile X community,” Budur said.The trial, which enrolled 215 patients with FXS aged 3 to under 30 years, aimed to assess the efficacy and safety of ZYN002, a pharmaceutically manufactured synthetic cannabidiol.CEO Jeffrey M. Dayno stated that the company has additional candidates in its pipeline. “We have a late-stage, catalyst-rich pipeline with multiple Phase 3 programs in the clinic and continue to be on track to initiate our Phase 3 trials for pitolisant HD in narcolepsy and idiopathic hypersomnia in the fourth quarter of this year,” he said.HRMY stock is down by 21% this year and by 28% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/honda-motor-reportedly-ends-us-production-of-acura-zdx-ev/chD14gFR33x">Honda Motor Reportedly Ends US Production Of Acura ZDX EV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study

The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.

Activist hedge fund Engine Capital is reportedly pushing Acadia Healthcare (ACHC) to refresh its board as it faces multiple federal investigations.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/e96d221b-c275-4b3e-86aa-250f784d55dc">report</a> by The Financial Times, the fund holds a roughly 3% stake in Acadia and has written a letter to the company's board, requesting a review of its asset portfolio, improvements to its board of directors, and the halting of capital-intensive projects for new facilities.Acadia provides for-profit behavioral healthcare services. It is currently facing probes from the Department of Justice and Securities and Exchange Commission over allegations of holding patients against their will and falsifying insurance claims, the report noted.Shares of the company rose over 8% on Wednesday morning following the news. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACHC">ACHC</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Tennessee-headquartered Acadia operated a network of 274 behavioral healthcare facilities, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics, with approximately 12,100 beds in 39 states and Puerto Rico as of the end of June. The company estimates that it serves more than 82,000 patients daily.As per FT, Engine Capital accused Acadia of maintaining a “growth at any cost” approach in its letter. It alleged that the approach has given rise to a bloated corporate structure and noted that a 2022 reorganisation left the company with an unwieldy management structure that has stifled the company’s turnaround.The firm also urged the company to add new directors with experience in behavioral health and capital allocation, while noting that the current board has no director with relevant operating experience. The hedge fund also encouraged the company to consider selling its assets and repurchasing shares.ACHC stock is down 40% this year and approximately 69% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uniqure-stock-rises-pre-market-after-investigational-huntingtons-disease-drug-slows-disease-in-trial/chD1GAOR33X">uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an Acadia Healthcare logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Acadia Healthcare Stock Surges After Activist Hedge Fund Reportedly Seeks Board Revamp

According to a report by The Financial Times, the fund has written a letter to the company's board, requesting a review of its asset portfolio and improvements to its board.

According to a report by The Financial Times, the fund holds a roughly 3% stake in Acadia and has written a letter to the company's board, requesting a review of its asset portfolio, improvements to its board, and the halting of capital-intensive projects for new facilities.

Acadia Pharmaceuticals Inc. (ACAD) announced on Tuesday that its late-stage intranasal Carbetocin trial in Prader-Willi syndrome (PWS) patients did not achieve a statistically significant improvement in hyperphagia.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-phase-3-compass-pws-trial">study</a> enrolled 175 children and adults aged five to 30 years with PWS, a rare genetic disorder characterized by an insatiable hunger or hyperphagia and a constant need for food, leading to obesity. However, intranasal Carbetocin did not demonstrate a statistically significant improvement over placebo to week 12 on the Hyperphagia Questionnaire for Clinical Trials, the company said.The firm noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials, with a low rate of adverse events.Shares of the company tumbled 11% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACAD">ACAD stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Acadia’s Head of Research and Development, Elizabeth HZ Thompson, said that the company is “disappointed” by these findings. “We are committed to sharing a summary of the data in the future to ensure learning for the PWS community; however, given these results, we do not intend to investigate intranasal carbetocin any further,” Thompson added.CEO Catherine Owen Adams highlighted that the firm’s approved products are projected to generate over $1 billion in net sales in 2025 despite the disappointment with the trial. The company’s drugs for the treatment of Rett syndrome and for treating hallucinations and delusions associated with Parkinson’s disease psychosis are approved by the U.S. Food and Drug Administration.“Looking ahead, we anticipate seven Phase 2 or 3 study starts through 2026 and four data readouts by the end of 2027,” the CEO added.ACAD stock is up 29% this year and approximately 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-mp-materials-stock-rising-today/chD1R9FR330">Why Is MP Materials Stock Rising Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Acadia Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study 

The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials.

Moderna (MRNA) said on Tuesday that its 2025-2026 formula of mNEXSPIKE demonstrated a strong immune response in recipients in a study.The updated formulation targets the LP.8.1 variant of the COVID-19-causing virus. Data from an ongoing phase 4, post-marketing study showed that the updated formula of mNEXSPIKE, on average, demonstrated a greater than 16-fold increase in neutralizing antibodies against the LP.8.1 variant, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6125971827149873&amp;symbol=MRNA">said</a>.A robust immune response was identified in individuals aged 12 to 64 years with at least one underlying condition that puts them at high risk for severe outcomes from an infection, as well as in all adults aged 65 years and older, the company added. The trial was evaluating the safety, tolerability, and immunogenicity of the new formula of mNEXSPIKE.<a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> rose over 1% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around MRNA stayed within ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Moderna stated that the safety profile of the vaccine in the study was consistent with that observed in previous studies. mNEXSPIKE received the approval of the U.S. Food and Drug Administration in late May.Earlier this month, the company also announced that the 2025-2026 formula of its other COVID-19 vaccine, Spikevax, showed, on average, a greater than 8-fold increase in neutralizing antibodies against the LP.8.1 variant in individuals participating in a Phase 4 study.Spikevax is approved by the FDA for individuals six months through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. mNEXSPIKE is only approved for individuals who are at least 12 years of age.MRNA stock is down 36% this year and approximately 59% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-rises-pre-market-after-ubs-raises-q3-delivery-estimate-mizuho-hikes-price-target/chDhMRBR35d">Tesla Stock Rises Pre-Market After UBS Raises Q3 Delivery Estimate, Mizuho Hikes Price Target</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Moderna Says Updated mNEXSPIKE Covid Shot Demonstrated Robust Immune Response In Study 

The trial was evaluating the safety, tolerability, and immunogenicity of the new formula of mNEXSPIKE.

BWXT Shares Climb On Department Of Energy’s $1.5B Contract

The Department of Energy stated that the pilot plant scope will be implemented through an Indefinite Delivery, Indefinite Quantity (IDIQ) contract vehicle, valued at $1.5 billion, utilizing discrete task orders.

RH Stock Sees Slew Of Downgrades, Price Target Cuts From Wall Street As Trump Tariffs Bite

Telsey Advisory Group stated that if an additional sector tariff on furniture is imposed, RH has the highest exposure within the home furnishings coverage group due to a high percentage of sales from furniture and limited sourcing in the U.S.

Legend Biotech Corp. (LEGN) is reportedly considering a second listing outside of the US.According to a Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-05/legend-biotech-is-said-to-explore-second-listing-outside-of-us">report</a> on Friday, which cited unnamed people familiar with the matter, the New Jersey-headquartered company has discussed a second listing option with potential advisers. The company may list in Hong Kong, Singapore, or London, the report stated, while noting that a second listing could help boost the company's valuation, particularly if in Hong Kong.Hong Kong is currently emerging as a hub for biotech company listing, and the city’s Hang Seng Biotech Index has surged more than 100% this year, the report added.However, the company is only considering a second listing and may eventually decide against it, sources told Bloomberg.<a href="https://stocktwits.com/symbol/LEGN">LEGN shares</a> traded 3% higher at the time of writing. On Stocktwits, retail sentiment around LEGN stayed within ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.In August, Legend reported second-quarter (Q2) adjusted net income of $10.1 million, compared to an adjusted net loss of $2.5 million for the three months ended June 30, 2024, and total revenue of $255.1 million. The company ended June with cash and cash equivalents, as well as time deposits, totaling $1 billion.Legend, founded in 2014, is centered in the U.S. despite having roots in China and employs over 2,800 people. It's known for Carvykti, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets in collaboration with Johnson &amp; Johnson.LEGN stock is up 11% this year but down approximately 33% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/immunome-stock-rises-after-craig-hellum-initiates-coverage-with-26-dollar-price-target/chwIWHxRdqE">Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Legend Biotech Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Legend Biotech Considering Second Listing Outside US: Report

According to a Bloomberg report, the New Jersey-based company has discussed the option with potential advisers.

AOR
iShares Core Growth Allocation ETF

Feed

News

Sentiment

Fundamentals

Info

Latest AOR News

AORiShares Core Growth Allocation ETF